Patent
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
1. A method of eliciting an immune response against Neisseria meningitidis comprising administering to a mammal an effective amount of a composition comprising at least two polypeptides selected from the group consisting of: (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71; (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 77; (c) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55; (d) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68; and (e) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66, wherein the composition comprises aluminum.
2. The method according to claim 1 , wherein the composition comprises (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 77.
3. The method according to claim 1 , wherein the composition comprises (a) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and (b) a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55.
4. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68.
5. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 71 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66.
6. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66.
7. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66 and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68.
8. The method according to claim 1 , wherein the composition comprises a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 55; a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 66; and a non-lipidated non-pyruvylated polypeptide comprising the amino acid sequence SEQ ID NO: 68.
9. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup A.
10. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup C.
11. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135.
12. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y.
13. The method according to claim 1 , further comprising administering to the mammal at least two immunogenic conjugates selected from:
a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup A
b) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup C
c) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and
a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y.
14. The method according to claim 1 , further comprising administering to the mammal at least three conjugates selected from:
a) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup A
b) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup C
c) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and
d) a conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y.
15. The method according to claim 1 , further comprising administering to the mammal an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup A; an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup C; an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup W135; and an immunogenic conjugate of a capsular saccharide of Neisseria meningitidis serogroup Y.